Armour Thyroid: EMA vs FDA Regulatory Approach

How the FDA Classifies Armour Thyroid

Armour Thyroid occupies a regulatory gray zone. It was sold in the United States before the Federal Food, Drug, and Cosmetic Act of 1938, which means it was never required to go through the formal New Drug Application process that modern pharmaceuticals must complete [1]. The FDA considers it an "unapproved drug" that is marketed under enforcement discretion, a status shared with a handful of other legacy products.

The Pre-1938 Grandfathering Loophole

Before 1938, drugs could be sold without proving safety or efficacy to federal regulators. Armour Thyroid, first introduced in the early 1900s by Armour and Company (a meatpacking firm that extracted thyroid glands from pigs), predates the modern regulatory framework entirely. When the 1938 Act took effect, products already on the market were allowed to continue selling without an NDA, provided their formulations did not change substantially [1].

This is not the same as FDA approval. The Drugs@FDA database does not list a standard approval letter for Armour Thyroid. The product appears in the FDA's records as a marketed unapproved drug.

The 2006 Compliance Push

In 2006, the FDA began the Unapproved Drugs Initiative, designed to bring legacy products into the modern approval framework [2]. Several categories of unapproved drugs were targeted. Thyroid preparations were flagged, but Armour Thyroid has continued to be marketed. The FDA has not taken enforcement action to remove it, likely because of its long history of clinical use and the absence of a clear safety signal that would justify market withdrawal.

The practical result: Armour Thyroid is legal to prescribe and dispense in every U.S. State, but it lacks the rigorous clinical-trial dossier that the FDA requires of drugs approved after 1962 [2].

USP Monograph Requirements

What Armour Thyroid does have is compliance with the United States Pharmacopeia (USP) monograph for thyroid tablets. This monograph specifies content uniformity standards for T4 and T3. Each grain (60 mg) must contain approximately 38 mcg of levothyroxine (T4) and 9 mcg of liothyronine (T3), with allowable variation within USP-defined limits [3]. This is a quality standard, not an efficacy standard. It confirms the pill contains what it claims but does not address whether the product performs as well as synthetic alternatives in controlled trials.

Why the EMA Has No Equivalent Product

The European Medicines Agency has never issued a centralized marketing authorization for Armour Thyroid or any other desiccated thyroid extract. The reasons are structural, scientific, and historical.

No Application Has Been Filed

No manufacturer has submitted a Marketing Authorization Application (MAA) to the EMA for a desiccated thyroid product [4]. Without a submission, there is nothing to evaluate. This is partly commercial (the European market for desiccated thyroid is small) and partly regulatory (the EMA would require a full dossier, including randomized controlled trials, that does not currently exist for any desiccated thyroid product).

National-Level Availability Varies

Some EU member states permit desiccated thyroid on a named-patient or special-import basis. In the United Kingdom (post-Brexit, regulated by the MHRA rather than the EMA), desiccated thyroid can be prescribed as a special or unlicensed medicine, but this requires the prescriber to accept personal liability for an unlicensed product [5]. France, Germany, and the Netherlands have similar mechanisms, though access is inconsistent and often depends on individual pharmacy willingness to source the product.

The EMA's Evidence Threshold

The EMA requires evidence of quality, safety, and efficacy for all new marketing authorizations. For a biologically derived product like desiccated thyroid (sourced from animal tissue), the agency would also require extensive characterization of the source material, batch-to-batch consistency data, and TSE (transmissible spongiform encephalopathy) risk assessments [4]. These requirements exceed what the USP monograph provides. No sponsor has been willing to invest in generating this data for a product with limited patent protection and a niche market.

What the Armour Thyroid Label Actually Says

The Armour Thyroid prescribing information, available through the Allergan (now AbbVie) product label, provides specific guidance that reflects its unique regulatory position [3].

Indications and Dosing

The label indicates Armour Thyroid for replacement or supplemental therapy in hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Starting doses are typically 15 to 30 mg daily, titrated in 15 mg increments every two to four weeks based on clinical response and thyroid function tests [3].

The label does not reference any key randomized controlled trial. This is a direct consequence of the grandfathered status. Drugs approved before the 1962 Kefauver-Harris Amendment were not required to demonstrate efficacy through controlled studies.

Black Box Warning

The label carries a black box warning stating that thyroid hormones, including thyroid extract, should not be used for the treatment of obesity or weight loss [3]. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or life-threatening toxicity, particularly when given with sympathomimetic amines such as those used for appetite suppression.

T3 Content and Monitoring

Because Armour Thyroid contains T3 (liothyronine), serum T3 levels peak roughly two to four hours after ingestion. The label advises monitoring TSH and free T4 but does not mandate routine T3 monitoring. Some endocrinologists check free T3 levels anyway, particularly when patients report symptoms suggestive of overreplacement (palpitations, anxiety, tremor) [6].

Head-to-Head Evidence: Desiccated Thyroid vs Levothyroxine

The evidence base comparing desiccated thyroid to synthetic levothyroxine is small. The most frequently cited trial is Hoang et al. (2013), published in the Journal of Clinical Endocrinology & Metabolism [6].

The Hoang et al. Trial

This crossover study enrolled 70 patients with hypothyroidism who were randomized to receive either desiccated thyroid extract or levothyroxine for 16 weeks, then switched to the other treatment for another 16 weeks. At the end of the study, there was no significant difference in TSH, cognitive function scores, or quality-of-life measures between the two groups [6]. Patients on desiccated thyroid lost an average of 1.5 kg more than those on levothyroxine, a modest difference. Nearly 49% of participants preferred desiccated thyroid, compared to 19% who preferred levothyroxine (the remainder had no preference) [6].

The trial was small and short. Sixteen weeks per arm is not long enough to assess long-term cardiovascular or bone effects of sustained T3 exposure.

What Guideline Bodies Say

The 2014 American Thyroid Association (ATA) guidelines for the treatment of hypothyroidism recommend levothyroxine monotherapy as the standard of care [7]. The guidelines note that there is insufficient evidence to recommend desiccated thyroid extract or combination T4/T3 therapy for routine use. The ATA does acknowledge that some patients report subjective preference for combination therapy, but the panel concluded that the evidence base does not support a change in the standard recommendation [7].

The European Thyroid Association (ETA) published a 2012 position statement on the use of L-T4 + L-T3 combination therapy, reaching a similar conclusion: insufficient evidence for routine recommendation, though an experimental basis for a trial of combination therapy in selected patients who remain symptomatic on levothyroxine alone [8].

Neither guideline body endorses desiccated thyroid as a first-line option.

Safety Profile and Post-Market Surveillance

FDA Adverse Event Reporting

Armour Thyroid adverse events are reported through the FDA's MedWatch system and can be queried through the FDA Adverse Event Reporting System (FAERS) [9]. Because Armour Thyroid is an unapproved drug, it does not participate in the same structured post-market surveillance programs (such as Risk Evaluation and Mitigation Strategies, or REMS) that apply to formally approved products.

Reported adverse events are predominantly related to overreplacement: tachycardia, atrial fibrillation, anxiety, insomnia, and weight loss. Bone mineral density concerns have been raised for long-term T3-containing regimens, though prospective data specific to desiccated thyroid are lacking [10].

The T3 Variable

The T4:T3 ratio in Armour Thyroid (approximately 4.2:1) does not match the human thyroid's secretion ratio (approximately 14:1) [7]. This means patients taking Armour Thyroid are exposed to supraphysiologic T3 relative to T4. The clinical significance of this mismatch is debated. Some clinicians argue that peripheral conversion of T4 to T3 is sufficient and that exogenous T3 adds unnecessary risk. Others point to deiodinase polymorphisms (particularly DIO2 Thr92Ala) that may impair T4-to-T3 conversion in a subset of patients, though this hypothesis remains unproven in large trials [11].

Batch Variability

A 2010 analysis published in Thyroid examined the potency of several thyroid hormone preparations and found that desiccated thyroid products met USP standards but exhibited wider batch-to-batch variability than synthetic levothyroxine [12]. The USP allows T4 content to range from 90% to 110% of the labeled amount. For a product containing both T4 and T3, this variability applies to each component independently, creating a wider effective dosing range than a single-ingredient synthetic product.

Regulatory Implications for Prescribers

United States

Prescribers in the U.S. Face no legal barrier to writing Armour Thyroid prescriptions. The drug is available through standard pharmacy channels and is covered by many insurance plans, though some require prior authorization. Pharmacies may substitute generic desiccated thyroid (such as NP Thyroid by Acella) unless the prescriber specifies "dispense as written" [3].

The American Association of Clinical Endocrinologists (AACE) and ATA do not prohibit desiccated thyroid prescribing but recommend that clinicians inform patients about its unapproved status and the limited comparative evidence [7].

European Union and United Kingdom

Prescribers in EU member states who wish to use desiccated thyroid must manage unlicensed medicine regulations. In the UK, the General Medical Council requires that prescribers document the clinical rationale for choosing an unlicensed product over a licensed alternative, confirm that no suitable licensed alternative exists, and take direct responsibility for patient outcomes [5]. In practice, this means most European prescriptions for desiccated thyroid are written by endocrinologists rather than general practitioners, and patients may face difficulty obtaining the product from community pharmacies.

Cross-Border Importation

Some European patients purchase Armour Thyroid from U.S. Or Thai pharmacies (where desiccated thyroid is available over the counter). This practice is not endorsed by any regulatory body and carries risks related to product authenticity, storage conditions during shipping, and lack of medical oversight [4].

What May Change

The FDA has not signaled imminent enforcement action against Armour Thyroid, but the regulatory field is not static. The Unapproved Drugs Initiative remains active, and any serious safety signal could trigger a reevaluation [2]. On the European side, no sponsor appears poised to submit an MAA.

The most likely catalyst for change would be a well-powered randomized controlled trial directly comparing desiccated thyroid to levothyroxine with hard endpoints (cardiovascular events, bone fractures, mortality). The ATA's 2014 guidelines specifically called for such a trial [7]. As of 2026, none has been completed.

For now, Armour Thyroid remains a drug available by regulatory inertia in the U.S. And by special exception in parts of Europe. Clinicians prescribing it should document the rationale, monitor TSH and free T4 (and consider free T3) at six- to eight-week intervals during dose adjustment, and counsel patients that the product's evidence base is thinner than that of synthetic levothyroxine [6][7].